Denosumab (Prolia, Xgeva▼): Risk of osteonecrosis of jaw and external auditory canal

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Denosumab is a human monoclonal IgG2 antibody. Denosumab (Prolia▼) 60 mg solution for injection is indicated for for the treatment of osteoporosis in postmenopausal women and for the treatment of bone loss associated with hormone ablation and prostate cancer for men at increased fracture risk. Denosumab (Xgeva▼) 120 mg solution for injection is indicated for the prevention of skeletal-related events like pathological fracture, radiation to bone, spinal cord compression, or surgery to bone in adults with bone metastases from solid tumours, and for the treatment of adults with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.

Five cases of osteonecrosis of the external auditory canal have been reported with use 60 mg denosumab. Th...

Recommended for you

  • Drug Updates
  • 1 comment

Brimonidine gel (Mirvaso): Risk of cardiovascular events if applied to damaged skin

Read more
  • Drug Updates
  • 1 comment

Denosumab (Prolia, Xgeva▼): Risk of osteonecrosis of jaw and external auditory canal

Read more
  • Drug Updates
  • 1 comment

Yellow Card Scheme Website: Report any side effects or safety concerns with e-cigarettes and e-liquids

Read more
  • Drug Updates
  • 1 comment

Restrictions to manage the risk for misuse of pseudoephedrine and ephedrine to be continued

Read more
  • Drug Updates
  • 1 comment

Finasteride 1 mg (Propecia): Reports of depression and suicidal thoughts in men

Read more
  • Drug Updates
  • no comment

Ponatinib (Iclusig▼): Risk of vascular arterial occlusion is dose-dependent

Read more
  • Drug Updates
  • 1 comment

Multiple sclerosis: Rebound syndrome after stopping fingolimod (Gilenya▼) or switching therapy

Read more
  • Drug Updates
  • 1 comment

Valproate (Epilim▼, Depakote▼): High risk of neurodevelopmental disability and birth defects

Read more
  • Drug Updates
  • 1 comment

Pilot website to report adverse reactions of psychoactive substances

Read more
  • Drug Updates
  • 1 comment

Canagliflozin (Invokana▼): Increased risk of lower limb amputation

Read more
  • Drug Updates
  • 1 comment

Posaconazole (Noxafil): tablets and oral suspension not interchangable

Read more
  • Drug Updates
  • 1 comment

Levonorgestrel-containing emergency contraceptives: interaction with hepatic enzyme inducers

Read more
  • Drug Updates
  • 1 comment

Idelalisib (Zydelig▼): updated safety information on risk of infection

Read more
  • Drug Updates
  • 1 comment

Lonsurf ▼(trifluridine/tipiracil) approved for colorectal cancer chemotherapy

Read more
  • Drug Updates
  • no comment

Riociguat (Adempas) contraindicated in pulmonary hypertension associated with idiopathic interstitial pneumonias

Read more
  • Drug Updates
  • no comment

Hyoscine butylbromide: serious adverse effects in cardiac patients

Read more
  • Drug Updates
  • 1 comment

Suspected fatal drug interaction between citalopram and cocaine

Read more
  • Drug Updates
  • 1 comment

Rare reports of calciphylaxis in patients taking warfarin

Read more
  • Drug Updates
  • 1 comment

N-acetylcysteine interference with Siemens assays: false-low test results

Read more
  • Drug Updates
  • 1 comment

Epclusa (sofosbuvir/velpatasvir) approved for treatment of chronic HCV infection

Read more
  • Drug Updates
  • 1 comment

Duavive (conjugated oestrogens/ bazedoxifene) approved for treatment of menopausal symptoms

Read more
  • Drug Updates
  • no comment

Drug safety alert: Minimizing cardiac side effects associated with concomitant use of apomorphine and domperidone

Read more
  • Drug Updates
  • 1 comment

Drug safety alert: Risks of PML, basal-cell carcinoma, and opportunistic infections associated with Fingolimod (Gilenya▼)

Read more
  • Drug Updates
  • 1 comment

Drug safety alert: Risk of diabetic ketoacidosis with SGLT2 inhibitors

Read more
  • Drug Updates
  • 1 comment

Drug safety update: Risk of progressive multifocal leukoencephalopathy with dimethyl fumarate (Tecfidera)

Read more
  • Drug Updates
  • 1 comment

Apremilast (Otezla▼): risk of psychiatric symptoms

Read more
  • Drug Updates
  • 1 comment

Direct-acting antivirals for chronic HCV (interferon-free): risk of hepatitis B reactivation

Read more
  • Drug Updates
  • 1 comment

Direct-acting antivirals for HCV and vitamin K antagonists: risk of interaction

Read more
  • Drug Updates
  • 1 comment

Brimonidine gel (Mirvaso▼): reports of symptom exacerbation

Read more
  • Drug Updates
  • 1 comment

Etoricoxib (Arcoxia): recommended starting dose revised

Read more